The brain is one of the most glucose-dependent organs in the body — consuming approximately 20% of total body glucose despite representing only 2% of body weight. This makes 2-DG’s effects on neural tissue particularly interesting, in both directions.

In epilepsy research, 2-DG has shown consistent anticonvulsant effects in animal models. The mechanism appears to involve multiple pathways: reduced glucose availability alters neuronal excitability, AMPK activation modulates synaptic transmission, and changes in BDNF expression have been observed. Several animal model studies have shown 2-DG reduces seizure frequency and severity.

In neurodegeneration research, 2-DG’s AMPK activation and mTOR inhibition are of interest. These pathways regulate autophagy — the cellular clearance of misfolded proteins — which is impaired in conditions like Alzheimer’s and Parkinson’s disease. Animal model studies have shown 2-DG administration increases autophagy markers and reduces toxic protein aggregation.

The neuroprotective and neuroactive effects of 2-DG present a double-edged picture: the same glucose restriction that may protect against neurodegeneration could theoretically stress neurons if sustained at high doses.

This article is for informational and educational purposes only. AuraDCA products are intended for research use only.